News - Appointments

Crescendo Biologics Ltd has promoted Theodora Harold to the position of chief executive officer, succeeding Peter Pack. She joined Crescendo in 2016 and is currently the chief financial officer.

Artios Pharma Ltd, a developer of cancer drugs, has appointed Ian Smith as chief medical officer to oversee the development of its portfolio of drugs that target DNA repair mechanisms. Dr Smith joins from Eli Lilly and Co where he was a senior medical director.

Bali Muralidhar, a medical doctor and experienced investor, has been named partner at Abingworth LLP, the London, UK-based investment group.

Joanne Jenkins, an oncology specialist, has joined iTeos Therapeutics SA as chief medical officer to help the Belgian company progress its portfolio of antibody therapeutics.

Andrea van Elsas, an immuno-oncology expert who directed some of the earliest research on pembrolizumab, has joined the scientific advisory board of InteRNA Technologies BV. The Dutch company has a pipeline of preclinical microRNA drug candidates for cancer.

Aprea Therapeutics AB has appointed Eyal Attar as chief medical officer to help drive the development of its anticancer therapies targeting the p53 tumour suppressor protein.

Munich, Germany-based Leukocare AG has appointed Andreas Seidl as chief operating officer and a member of the executive board to manage its technology platform for improving the stability and quality of biologics.

Martin Edwards, a senior partner of Novo Holdings A/S, has joined Verona Pharma Plc’s board of directors as a non-executive director. Novo holds 11.76% of Verona’s stock.

John Haurum, the former chief executive of F-star Biotechnology Ltd, has joined NeoPhore Ltd as a non-executive director to help oversee the company’s immunotherapy programme.

Sasa Leskovsek, a former Sanofi SA executive, has joined Ethypharm Group as chief scientific officer to help the company build its portfolio in pain management.